Showing results (181-190 of 202) with videos related to
Sort By:
Pageof 21
Biotechnology Research International|March 24, 2016
Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic MalignanciesMahmoud Aljurf, Hala Abalkhail, Amal Alseraihy, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2005
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemiaFrancis Giles, Srdan Verstovsek, Deborah Thomas, et al.Leukemia Research|May 3, 2005
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromesFrancis J Giles, Hagop M Kantarjian, Jorge E Cortes, et al.Leukemia Research|April 1, 2006
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemiaFrancis Giles, Srdan Verstovsek, Stefan Faderl, et al.Frontiers in Oncology|July 1, 2022
Reliability of Cell-Free DNA and Targeted NGS in Predicting Chromosomal Abnormalities of Patients With Myeloid NeoplasmsAndrew Ip, Alexandra Della Pia, Gee Youn Geeny Kim, et al.Cancer|March 15, 2006
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyHagop Kantarjian, Jean-Pierre J Issa, Craig S Rosenfeld, et al.The New England Journal of Medicine|June 16, 2006
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALLHagop Kantarjian, Francis Giles, Lydia Wunderle, et al.Blood Advances|December 13, 2018
GATA2 deficiency and human hematopoietic development modeled using induced pluripotent stem cellsMoonjung Jung, Stefan Cordes, Jizhong Zou, et al.Journal of Hematology & Oncology|October 24, 2025
B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemiaAshley Varkey, Manpreet Bariana, Mark Batistick, et al.Cancer|April 4, 2003
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseasesFrancis J Giles, Maureen A Cooper, Lewis Silverman, et al.Pageof 21